エザベンリマブと併用したオブリキスタミグ（BI 764532）の異なる用量が、DLL3陽性の小細胞肺がんおよびその他の神経内分泌腫瘍の患者にどの程度忍容されるかを検証する研究

基本情報

NCT ID

NCT05879978

ステータス

実施中（募集終了）

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

45

治験依頼者名

Boehringer Ingelheim

概要

This study is open to adults with small cell lung cancer and other neuroendocrine tumours that are positive for the tumour marker Delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of obrixtamig that people can tolerate when taken together with another medicine called ezabenlimab. Obrixtamig and ezabenlimab may help the immune system fight cancer. Participants get obrixtamig and ezabenlimab as infusions into a vein. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about every week. The visits also depend on the response to the treatment. At the study visits, the doctors check the health of the participants, take necessary laboratory tests, and note any health problems that could have been caused by the study treatment.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)